Management of Dementia with Behavioral Disturbances

Introduction to Non-Pharmacological Interventions

The American Academy of Neurology recommends beginning with non-pharmacological interventions as first-line treatment for all behavioral disturbances in dementia, reserving medications only for severe, persistent symptoms that fail environmental and behavioral approaches or pose significant safety risks 1, 2, 3

The DICE approach (Describe, Investigate, Create, Evaluate) is used to systematically assess behavioral symptoms, with the "Describe" step involving detailed documentation of behaviors, antecedents, and consequences using ABC charting over several days to identify environmental triggers 1, 2
The "Investigate" step includes examining underlying medical causes such as urinary tract infections, other systemic infections, dehydration, constipation, uncontrolled pain, and medication effects (particularly anticholinergic agents) 2, 3, 4

Establishing structured daily routines with predictable activities, regular physical exercise, consistent meal times, and fixed bedtimes can reduce confusion and anxiety 2, 4
Ensuring adequate bright light exposure during daytime (2 hours in the morning at 3,000-5,000 lux) can regulate circadian rhythms 2
Reducing nighttime light and noise can create favorable sleep environments 2
Removing potential hazards, installing safety features, minimizing glare and household clutter, and eliminating mirrors or reflective surfaces can reduce hallucinations 3, 4
Using orientation aids including calendars, clocks, and color-coded labels for navigation can help patients 4
Implementing tailored activity-based interventions matched to individual abilities and preferences can increase positive affect and reduce agitation 1
Increasing daytime physical and social activities can promote better sleep-wake cycles 2
Using calm tones, simple single-step commands, and gentle touch for reassurance can reduce anxiety 2, 3, 4
Applying the "three R's" approach: repeat instructions, reassure the patient, and redirect attention away from anxiety-provoking situations can be beneficial 4
Explaining procedures using simple language and breaking complex tasks into manageable steps can reduce confusion 4
Avoiding harsh tones, complex multi-step commands, open-ended questions, and confrontational approaches is recommended 2, 3, 4

Educating caregivers that behaviors are disease symptoms, not intentional actions, can reduce anxiety and distress 2, 3
Providing training in problem-solving techniques and supported conversation methods, particularly for patients with aphasia, can be helpful 1
Offering regular support and stage-specific education with anticipatory guidance for disease progression can improve caregiver outcomes 5

Considering pharmacological treatment only when non-pharmacological approaches have been ineffective, behaviors pose significant safety risks, or the patient experiences severe distress from symptoms is recommended 2, 3, 4
For agitation, referring to detailed guidelines on managing agitation in dementia for specific pharmacological considerations is advised 1
Avoiding medications with significant anticholinergic effects as they worsen cognitive symptoms is recommended 4
For psychosis/hallucinations, using cholinesterase inhibitors (rivastigmine) as preferred treatment for visual hallucinations in Lewy body dementia can be effective 3
For severe, persistent psychotic symptoms, considering atypical antipsychotics (risperidone, olanzapine, quetiapine) with extreme caution is recommended 3
For depression, considering SSRIs with minimal anticholinergic effects for anxiety with depression can be beneficial 4
For anxiety, considering SSRIs for anxiety with depressive features or using low-dose atypical antipsychotics only with careful monitoring can be helpful 4
For sleep disturbances, considering melatonin, though evidence is inconsistent, can be an option 2
For disinhibition, SSRIs may be considered, used with caution 2

Cholinesterase inhibitors may provide modest benefit for behavioral symptoms in Alzheimer's disease, particularly in later stages 3
Evidence for memantine in adults with Down syndrome and dementia is discouraging, showing no significant improvement versus placebo at 1-year follow-up 5

Evaluating response to pharmacological interventions within 30 days is recommended 2, 3, 4
Conducting close follow-up to monitor for adverse effects including extrapyramidal symptoms, metabolic changes, neuroleptic malignant syndrome, and tardive dyskinesia is necessary 2, 3, 4
Considering tapering or discontinuing medications after 6 months of symptom stabilization can be beneficial 2, 3, 4
Regularly reassessing the need for continued medication as neuropsychiatric symptoms fluctuate throughout dementia progression is advised 4

Assessing and monitoring for safety risks related to autonomy and decision-making capacity, behavioral status, environmental factors, fall risk, and activities of daily living is crucial 1
Developing an individualized safety plan in partnership with the patient, family, and healthcare team can reduce risks 1
Considering occupational and physical therapy consultations to enable current function and sustain activities of daily living can be helpful 5

Not relying solely on medications without implementing non-pharmacological strategies first is recommended 4
Not underestimating pain and discomfort as causes of behavioral disturbances is crucial 2, 4
Not using inappropriate communication techniques such as complex commands or harsh tones is advised 4
Not failing to monitor for medication side effects, which can sometimes exacerbate behavioral symptoms, is necessary 4